DEF 14A: BioAge Labs Sets Date for 2025 Annual Stockholders Meeting, Seeks Director Elections and Auditor Ratification

BioAge Labs will hold its 2025 Annual Meeting of Stockholders virtually on June 5, 2025, to elect directors and ratify the appointment of KPMG LLP as its independent auditor.

Summary

• BioAge Labs, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on June 5, 2025, at 3:30 p.m. Eastern Standard Time.
• Stockholders will vote to elect three Class I directors for a three-year term and to ratify the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The Board of Directors recommends voting FOR the election of each Class I director nominee and FOR the ratification of KPMG LLP's appointment.
• The record date for determining stockholders eligible to vote is April 10, 2025.
• Proxy materials are available online, and stockholders can vote via the internet, telephone, or mail.
• The company's common stock outstanding and entitled to vote as of April 10, 2025, was 35,850,037 shares.
• The Board of Directors has adopted a Compensation Recovery Policy ('Clawback Policy') to comply with new rules and regulations promulgated by the SEC.
• The company's non-employee directors receive annual cash compensation of $40,000 for service on the Board of Directors and additional cash compensation for the chairperson and committee members.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, presenting factual information about the upcoming annual meeting and corporate governance matters. The tone is professional and neutral, with a slight positive sentiment due to expressions of gratitude and anticipation from management.

Positives

• The company is providing stockholders with multiple options for voting, including online, telephone, and mail.
• The Board of Directors is actively involved in risk oversight, including cybersecurity risk management.
• The company has a Compensation Recovery Policy ('Clawback Policy') in place to recover incentive-based compensation from Covered Employees in the event of a restatement of our financial statements due to material noncompliance with any financial reporting requirements under the federal securities laws.
• The company has adopted an Insider Trading Policy that applies to all of our employees, officers and directors, including our Chief Executive Officer and other executive officers, to establish policies and procedures to promote compliance with applicable U.S. securities laws, rules and regulations and applicable Nasdaq listing standards and prohibit the purchase, sale and/or other dispositions of Company securities while in the possession of material nonpublic information related to the Company and the disclosure of material nonpublic information related to the Company to any outside person.

Risks

• The document mentions cybersecurity risks and the importance of maintaining the trust and confidence of stakeholders by protecting information technology systems, infrastructure, and data.
• The document mentions the risk of material noncompliance with any financial reporting requirements under the federal securities laws.

Future Outlook

The document outlines the business to be transacted at the Annual Meeting, including the election of directors and the ratification of the independent auditor, indicating a focus on corporate governance and financial oversight for the upcoming year.

Management Comments

• Jean-Pierre Garnier, Ph.D., Chair of the Board, thanks stockholders for their continued support and expresses anticipation for the Annual Meeting.
• Kristen Fortney, Ph.D., Chief Executive Officer and President, encourages stockholders to read the proxy statement and vote their shares.

Industry Context

As a biotechnology company, BioAge Labs' focus on corporate governance, director independence, and risk oversight aligns with industry best practices and regulatory requirements for publicly traded companies. The election of directors and ratification of auditors are standard procedures for maintaining transparency and accountability to stockholders.

Comparison to Industry Standards

• The corporate governance practices outlined in the document, such as director independence and committee structures, are consistent with Nasdaq listing requirements and SEC regulations, similar to companies like Amgen, Gilead Sciences, and Biogen.
• The compensation structure for non-employee directors, including cash retainers and equity grants, is comparable to industry standards for biotech companies of similar size and stage, such as those reported by MyoKardia (acquired by Bristol Myers Squibb) and Principia Biopharma (acquired by Sanofi).
• The Audit Committee's responsibilities, including oversight of financial reporting, internal controls, and cybersecurity risk, align with best practices recommended by organizations like the AICPA and COSO, similar to the practices of companies like Vertex Pharmaceuticals and Incyte.

Corporate Governance

Related Party Transactions

• In February 2024, the company sold Series D Preferred Stock to entities affiliated with directors and major stockholders, including Andreessen Horowitz, Cormorant, Longitude Venture Partners, Sofinnova Venture Partners, RA Capital, Khosla Ventures and Horsley Bridge.
• Sofinnova Venture Partners XI, L.P., purchased $10.6 million in shares of common stock in a concurrent private placement at the IPO price of $18.00 per share.
• Certain principal stockholders and their affiliated entities purchased an aggregate of 1,827,777 shares of common stock in the initial public offering on September 26, 2024 at the initial public offering price of $18.00 per share.
• Lingling Chen, M.D., the spouse of Dr. Morgen, our Chief Operating Officer, is employed by the Company in a non-executive officer position.

Stakeholder Impact

• Shareholders are asked to vote on key corporate governance matters, influencing the direction and oversight of the company.
• Employees are subject to the Code of Business Conduct and Ethics and the Insider Trading Policy, promoting ethical behavior and compliance with securities laws.
• Executive officers are subject to the Compensation Recovery Policy, aligning their incentives with the company's financial performance and reporting accuracy.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold the Annual Meeting on June 5, 2025, to conduct the business described in the proxy statement.
• The company will file the final voting results with the SEC in a Current Report on Form 8-K within four business days of the Annual Meeting.

Key Dates

Keywords

Annual Meeting, Stockholders, Directors, KPMG, Proxy Statement, Corporate Governance, Executive Compensation, Audit Committee, BioAge Labs